Researchers announce the first patient has been dosed in a trial testing remestemcel-L, a stem cell therapy, in severe COVID-19 patients on ventilators.
Testing of an experimental COVID-19 stem cell therapy has begun in the US. The therapy has been developed to treat hospitalised COVID-19 patients with moderate to severe acute respiratory distress syndrome (ARDS) who are on ventilators. A total of 300 are expected to be recruited into the randomised, placebo-controlled trial.
Comments are closed.